In the past week, IDYA stock has gone down by -0.18%, with a monthly decline of -8.82% and a quarterly plunge of -0.62%. The volatility ratio for the week is 3.52%, and the volatility levels for the last 30 days are 3.73% for Ideaya Biosciences Inc The simple moving average for the past 20 days is -4.56% for IDYA’s stock, with a -9.37% simple moving average for the past 200 days.
Is It Worth Investing in Ideaya Biosciences Inc (NASDAQ: IDYA) Right Now?
The 36-month beta value for IDYA is at 0.85. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 7 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IDYA is 76.56M, and currently, shorts hold a 14.92% of that float. The average trading volume for IDYA on September 19, 2024 was 837.16K shares.
IDYA) stock’s latest price update
The stock price of Ideaya Biosciences Inc (NASDAQ: IDYA) has surged by 3.72 when compared to previous closing price of 34.75, but the company has seen a -0.18% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-08-30 that SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 29, 2024, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 34,000 shares of the Company’s common stock to a newly hired employee.
Analysts’ Opinion of IDYA
Many brokerage firms have already submitted their reports for IDYA stocks, with Mizuho repeating the rating for IDYA by listing it as a “Outperform.” The predicted price for IDYA in the upcoming period, according to Mizuho is $50 based on the research report published on July 08, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see IDYA reach a price target of $55. The rating they have provided for IDYA stocks is “Buy” according to the report published on March 08th, 2024.
SVB Securities gave a rating of “Outperform” to IDYA, setting the target price at $33 in the report published on August 08th of the previous year.
IDYA Trading at -7.72% from the 50-Day Moving Average
After a stumble in the market that brought IDYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.49% of loss for the given period.
Volatility was left at 3.73%, however, over the last 30 days, the volatility rate increased by 3.52%, as shares sank -9.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.35% lower at present.
During the last 5 trading sessions, IDYA fell by -0.11%, which changed the moving average for the period of 200-days by +14.04% in comparison to the 20-day moving average, which settled at $37.58. In addition, Ideaya Biosciences Inc saw 1.30% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IDYA starting from Jason Throne, who proposed sale 75,000 shares at the price of $40.22 back on Aug 26 ’24. After this action, Jason Throne now owns shares of Ideaya Biosciences Inc, valued at $3,016,500 using the latest closing price.
WHITE MICHAEL ANTHONY, the Chief Scientific Officer of Ideaya Biosciences Inc, sale 28,500 shares at $36.24 during a trade that took place back on May 29 ’24, which means that WHITE MICHAEL ANTHONY is holding 0 shares at $1,032,884 based on the most recent closing price.
Stock Fundamentals for IDYA
Current profitability levels for the company are sitting at:
- -16.0 for the present operating margin
- 0.65 for the gross margin
The net margin for Ideaya Biosciences Inc stands at -12.85. The total capital return value is set at -0.21. Equity return is now at value -21.45, with -20.48 for asset returns.
Based on Ideaya Biosciences Inc (IDYA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -69.89. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -7.63.
Currently, EBITDA for the company is -130.42 million with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 238.77. The receivables turnover for the company is 11961.0for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.50.
Conclusion
In conclusion, Ideaya Biosciences Inc (IDYA) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
